Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients

Scandinavian Journal of Gastroenterology

Volumn 34, Issue 11, 1999, Pages 1139-1143

  Ito, H ^a   Miki, C ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colon cancer; Interleukin 1 receptor antagonist; Interleukin 6

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKINE; IMMUNOSUPPRESSIVE ACID PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CANCER PATIENT; COLON MUCOSA; COLORECTAL CANCER; DISEASE COURSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; RECEPTORS, INTERLEUKIN-1; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032746128     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655299750024959     Document Type: Article

References (29)

1. 1. Oka M, Iizuka N, Yamamoto K, et al. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996;16:1001-6.
2. 2. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83-5.
3. 3. Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989;250:607-10.
4. 4. Reichner JS, Mulligan JA, Palla ME, Hixson DC, Albina JE, Bland KI. Interleukin-6 production by rat hepatocellular carcinoma cell is associated with metastatic potential but not with tumorigenicity. Arch Surg 1996;131:360-5.
5. 5. Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leukemia Lymphoma 1998;30:56-571.
6. 6. Hoheisel G, Izbicki G, Roth M, et al. Proinflammatory cytokine levels in patients with lung cancer and carcinomatous pleurisy. Respiration 1998;65:183-6.
7. 7. Akimoto S, Okumura A, Fuse H. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocrine J 1998;45:183-9.
8. 8. Lissoni P, Rovelli F, Tisi E, et al. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors. J Biol Regul Homeost Agents 1995;9: 146-14.
9. 9. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects tumor proliferative activity in colorectal cancer patients. Cancer 1999;85:2526-31.
10. 10. Jordan M, Otterness IG, Ng R, et al. Neutralization of endogenous IL-6 suppresses induction of IL-I receptor antagonist. J Immunol 1995;154:4081-90.
11. 11 Rimaniol AC, Zylberberg H, Rabian C, et al. Imbalance between IL-1 and IL-1 receptor antagonist in the cerebrospinal fluid of HIV-intected patients. J Acq Immune Def Synd 1997;16:340-2.
12. 12. Lu ZY, Bataille R, Poubelle P, et al. An interleukin 1 receptor antagonist blocks the IL-1 induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. Stem Cells 1995;2:28-34.
13. 13. Yin M, Gopal V, Banavali S, et al. Effects of an TL-1 receptor antagonist on acute myeloid leukemia cells. Leukemia 1992;6: 898-901.
14. 14. Vidal-Vanaclocha F, Amezaga C, Asumendi A, et al. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res 1994;54: 2667-72.
15. 15. Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 as an antiinflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113-8.
16. 16. Nowacki MP, Janik P, Nowacki PM. Inflammation and metastases. Med Hypotheses 1996;47:193-6.
17. 17. Vidal-Vanaclocha F, Alvarez A, Asumendi A, et al. Interleukin 1-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. J Natl Cancer Inst 1996;88: 198-205.
18. 18. von Biberstein SE, Spiro JD, Lindquist R, et al. Interleukin-1 receptor antagonist in head and neck squamous cell carcinoma. Arch Otolaryngol 1996;122:751-9.
19. 19. Iwagaki H, Hizuta A, Tanaka N. Interleukin-1 receptor antagonists and other markers in colorectal cancer patients. Scand J Gastroenterol 1997;32:577-81.
20. 20. von Biberstein SE, Spiro JD, Lindquist R, Kreutzer DL. Interleukin-1 receptor antagonist in head and neck squamous cell carcinoma. Arch Otolaryngol 1996;122:751-9.
21. 21. Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219:325-31.
22. 22. Staal-van den Brekel AJ, Dentener MA, et al. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995;13:2600-5.
23. 23. Wigmore SJ, Fearson KC, Maingay JP, et al. Down regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 1997;92:215-21.
24. 24. Fujiki F, Mukaida N, Hirose K, et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res 1997;57:94-9.
25. 25. Tamura K, Shibata Y, Matsuda Y, Ishida N. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluid of cancer patients. Cancer Res 1981;41:3244-52.
26. 26. Oka M, Mitsunaga H, Hazama S, Yoshino S, Suzuki T. Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers. Jpn J Surg 1993;23: 669-74.
27. 27. Henderson B, Thompson RC, Hardingham T, et al. Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine 1991;9:246-9.
28. 28. Alexander HR, Doherty GM, Venzon DJ, et al. Recombinant interleukin-1 receptor antagonist: effective therapy against gram-negative sepsis in rats. Surgery 1992;112:188-94.
29. 29. Corninelli F, Nast CC, Duchini A, et al. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992;103:65-71.